Search results for "Kidney"

showing 10 items of 1514 documents

Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19

2020

Hospital admissions and mortality from the Coronavirus disease 2019 (COVID-19) pandemic are spreading throughout the world, and second and third waves are thought to be likely. Risk factors for severe COVID-19 include diabetes, chronic kidney disease and cardiovascular disease. Currently, there is no vaccine and no approved therapy. Therapeutic approaches are aimed at preventing viral replication and spread, limiting the impact of the inflammatory overdrive (cytokine storm), preventing thromboembolic complications and replacing or supporting organ function. However, despite organ support, mortality is currently 65% for those receiving advanced respiratory support and 78% for those requiring…

medicine.medical_specialtyempagliflozinEmpagliflozinlcsh:MedicineContext (language use)ReviewDisease030204 cardiovascular system & hematologyCardiovascularSGLT203 medical and health scienceschemistry.chemical_compound0302 clinical medicineChronic kidney diseaseDiabetes mellitusmedicine030212 general & internal medicineCanagliflozinDapagliflozincanagliflozinIntensive care medicinediabetesbusiness.industrycardiovascularDiabeteslcsh:RCOVID-19dapagliflozinGeneral MedicineDapagliflozinmedicine.diseaseVirusClinical trialRespiratory failurechemistryCytokine stormbusinesschronic kidney diseaseKidney diseaseJournal of Clinical Medicine
researchProduct

Impact of Non-Alcoholic Fatty Liver Disease on Metabolic Comorbidities in Type 2 Diabetes Mellitus.

2021

Abstract Objective Type 2 Diabetes (T2D) is a major risk factor for the development and progression of non-alcoholic fatty liver disease (NAFLD). The published prevelance in epidemiological studies in this high risk population exceeds 70%. The aim of this analysis was to investigate the impact of NAFLD on T2D patients in Germany. Methods Using the Disease Analyzer Database (IQVIA), T2D patients with NAFLD diagnosed in Germany were matched to a cohort without NAFLD controlling for age, sex, physician, index year and metabolic comorbidities and assessed for their risk of developing myocardial infarction, stroke, peripheral arterial disease (PAD) or chronic kidney disease, as well as the type …

medicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and MetabolismPopulationType 2 diabetesComorbidity03 medical and health sciencesLiver disease0302 clinical medicineEndocrinologyNon-alcoholic Fatty Liver DiseaseRisk FactorsInternal medicineEpidemiologyInternal MedicinemedicineHumansInsulinRisk factoreducationeducation.field_of_studybusiness.industryFatty livernutritional and metabolic diseasesType 2 Diabetes MellitusGeneral Medicinemedicine.diseasedigestive system diseasesDiabetes Mellitus Type 2030220 oncology & carcinogenesis030211 gastroenterology & hepatologybusinessKidney diseaseExperimental and clinical endocrinologydiabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
researchProduct

Factors Predisposing to Hypertension in Subjects Formerly Born Preterm: Renal Impairment, Arterial Stiffness, Endothelial Dysfunction or 
Something E…

2020

: Subjects formerly born preterm subsequently develop arterial - particularly isolated systolic- hypertension more frequently than their peers born at term. : Numerous factors may influence this predisposition, including an incomplete nephrogenesis, implying the presence of kidneys with a reduced number of nephrons and consequent reduction in haematic filtration, increased sodium absorption and activation of renin-angiotensin-aldosterone system, increased arterial rigidity produced by an elastin deficiency previously observed in anatomic specimens of human immature aorta, and reduced endothelial nitric oxide excretion, due to high blood levels of ADMA, a strong direct inhibitor of nitric o…

medicine.medical_specialtyhypertensionIntrauterine growth restrictionGestational Age030204 cardiovascular system & hematologyKidneyRisk AssessmentArticleNitric oxideExcretion03 medical and health scienceschemistry.chemical_compound0302 clinical medicineVascular StiffnessRisk FactorsInternal medicinemedicine.arteryInternal MedicineMedicineHumans030212 general & internal medicinelow birth weightEndothelial dysfunctionAortaFetal Growth Retardationbiologybusiness.industryInfant Newbornpreterm birthblood pressureperinatal programmingmedicine.diseaseEndocrinologyBlood pressurechemistryArterial stiffnessbiology.proteinEndothelium VascularbusinessPrematurityElastinInfant PrematureCurrent Hypertension Reviews
researchProduct

Serum Uric Acid and Kidney Disease Measures Independently Predict Cardiovascular and Total Mortality: The Uric Acid Right for Heart Health (URRAH) Pr…

2021

Background: Serum uric acid predicts the onset and progression of kidney disease, and the occurrence of cardiovascular and all-cause mortality. Nevertheless, it is unclear which is the appropriate definition of hyperuricemia in presence of chronic kidney disease (CKD). Our goal was to study the independent impact of uric acid and CKD on mortality.Methods: We retrospectively investigated 21,963 patients from the URRAH study database. Hyperuricemia was defined on the basis of outcome specific cut-offs separately identified by ROC curves according to eGFR strata. The primary endpoints were cardiovascular and all-cause mortality.Results: After a mean follow-up of 9.8 year, there were 1,582 (7.2…

medicine.medical_specialtyhyperuricemiaCardiovascular Medicineurologic and male genital diseasesGastroenterologyalbuminuriachemistry.chemical_compoundcardiovascular mortalityInternal medicinemedicineeGFRDiseases of the circulatory (Cardiovascular) systemHyperuricemiaRisk factorOriginal Researchbusiness.industryIncidence (epidemiology)Confoundingalbuminuria; all-cause mortality; cardiovascular mortality; eGFR; hyperuricemiahyperuricemia eGFR albuminuria cardiovascular mortality all-cause mortalitymedicine.diseasechemistryQuartileRC666-701AlbuminuriaUric acidall-cause mortalitymedicine.symptomCardiology and Cardiovascular MedicinebusinessKidney disease
researchProduct

Blood pressure in chronic kidney disease stage 5D—report from a Kidney Disease: Improving Global Outcomes controversies conference

2010

Management of blood pressure (BP) in patients with chronic kidney disease receiving dialysis (stage 5D) provides a significant challenge for healthcare professionals. The association between BP and cardiovascular disease risk has been well studied in the general population; however, in dialysis patients, physiological and dialysis-related mechanisms influencing BP are complex, and the associated risk is poorly understood. In stage 5D, BP is determined by the complex interplay of fluid volume and prescription of post-dialysis target weight, sodium load, the renin–angiotensin and sympathetic nervous systems, and diverse exogenous factors, such as administration of erythropoiesis-stimulating a…

medicine.medical_specialtyhypotensionhypertensionmedicine.medical_treatmentPopulationLeft ventricular hypertrophylaw.inventionRandomized controlled triallawMedicineantihypertensiveMedical prescriptioneducationIntensive care medicinesodium managementDialysiseducation.field_of_studybusiness.industryGuidelinemedicine.diseaseBlood pressureNephrologydialysisbusinesschronic kidney diseaseKidney diseaseKidney International
researchProduct

Mortality Risk Assessment at the Admission in Patient With Proximal Femur Fractures: Electrolytes and Renal Function

2021

In patients over 65y.o. who were surgically treated for a hip fracture, electrolytes have not been specifically studied as predictors of mortality. The main purpose of this study was to assess whether electrolytes and chronic kidney disease (CKD) stages, evaluated at admission, could represent a pre-operative prognostic factor in this population. Moreover, the role of epidemiological and clinical parameters was analyzed with and without a surgical timing stratification. This retrospective study included 746 patients. For each patient, their age, gender, fracture classification, Hb value, comorbidities, ASA class, chronic kidney disease, creatinine levels, electrolytes and surgical timing w…

medicine.medical_specialtykidneytrauma surgeryRenal functionfragility fractureelectrolyteselectrolytelcsh:Geriatricslcsh:Orthopedic surgeryGeriatric traumabasic researchmedicineOrthopedics and Sports MedicineIn patientGeriatricsKidneyHip fractureResident Cornerbusiness.industrygeriatric medicineRehabilitationfragility fracturesmedicine.diseasemortalitySurgerylcsh:RD701-811lcsh:RC952-954.6medicine.anatomical_structurehip fracturemortality riskSurgerygeriatric traumaGeriatrics and GerontologybusinessRisk assessmentTrauma surgery
researchProduct

Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?

2015

Current therapy directed at delaying the progression of diabetic nephropathy includes intensive glycemic and optimal blood pressure control, renin angiotensin-aldosterone system blockade and multifactorial intervention. However, the renal protection provided by these therapeutic modalities is incomplete. There is a scarcity of studies analysing the nephroprotective effect of antihyperglycaemic drugs beyond their glucose lowering effect and improved glycaemic control on the prevention and progression of diabetic nephropathy. This article analyzes the exisiting data about older and newer drugs as well as the mechanisms associated with hypoglycemic drugs, apart from their well known blood gluc…

medicine.medical_specialtylcsh:MedicineReviewPharmacologyalbuminuriaDiabetic nephropathyDDP4 inhibitorsDiabetes mellitusantihyperglycemic drugsSGLT2 inhibitionRenin–angiotensin systemDiabetic nephropathiesmedicineIntensive care medicineGlycemicnephroprotectionKidneyDiabetisdiabetic chronic kidney diseasebusiness.industrydiabetic nephropathylcsh:RDiabetesGeneral MedicineNefropaties diabètiquesmedicine.diseaseBlockadeClinical trialmedicine.anatomical_structurediabetes mellitusAlbuminuriaglucagon-like peptide agonistsmedicine.symptombusiness
researchProduct

Use of neural networks for dosage individualisation of erythropoietin in patients with secondary anemia to chronic renal failure.

2003

The external administration of recombinant human erythropoietin is the chosen treatment for those patients with secondary anemia due to chronic renal failure undergoing periodic hemodialysis. The goal is to carry out an individualised prediction of the erythropoietin dosage to be administered. It is justified because of the high cost of this medication, its secondary effects and the phenomenon of potential resistance which some individuals suffer. One hundred and ten patients were included in this study and several factors were collected in order to develop the neural models. Since the results obtained were excellent, an easy-to-use decision-aid computer application was implemented.

medicine.medical_specialtymedicine.diagnostic_testAnemiaSecondary anemiabusiness.industrymedicine.medical_treatmentHealth InformaticsAnemiamedicine.diseaseRecombinant ProteinsComputer Science ApplicationsTherapeutic drug monitoringErythropoietinmedicineQuality of LifeChronic renal failureHumansKidney Failure ChronicIn patientHemodialysisNeural Networks ComputerIntensive care medicinebusinessErythropoietinmedicine.drugComputers in biology and medicine
researchProduct

Neutrophil Gelatinase-Associated Lipocalin for Acute Kidney Injury During Acute Heart Failure Hospitalizations

2016

AbstractBackground: Worsening renal function (WRF) often occurs during acute heart failure (AHF) and can portend adverse outcomes; therefore, early identification may help mitigate risk. Neutrophil...

medicine.medical_specialtymedicine.drug_class030232 urology & nephrologyRenal functionCardiorenal syndrome030204 cardiovascular system & hematologyLipocalin03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicineNatriuretic peptideIntensive care medicineProspective cohort studyCreatininebusiness.industryAcute kidney injuryfood and beveragesmedicine.disease3. Good healthchemistryHeart failureCardiologyCardiology and Cardiovascular MedicinebusinessJournal of the American College of Cardiology
researchProduct

Clinical pharmacokinetics of atenolol — A review

1982

Atenolol is a hydrophilic betareceptor blocking drug, which is predominantly eliminated via the kidneys, only about 5% of the atenolol is metabolised by the liver. After oral administration atenolol is incompletely absorbed from the intestine, so about 50% of the beta blocker are finally biovailable. In plasma only 3% of atenolol are protein-bound. There exists a linear relationship between the atenolol plasma levels and the degree of beta blocking effect measured by inhibition of the exercise-induced tachycardia. No correlation was found between plasma levels of atenolol and blood pressure lowering activity of the drug. After oral administration elimination half life of atenolol is calcula…

medicine.medical_specialtymedicine.drug_classAdministration OralBiological AvailabilityRenal functionPharmacologyKidneyIntestinal absorptionPropanolaminesPharmacokineticsRenal DialysisOral administrationInternal medicinemedicineHumansDrug InteractionsPharmacology (medical)cardiovascular diseasesBeta blockerPharmacologyChemistryLiver DiseasesKidney metabolismAtenololKineticsEndocrinologyAtenololIntestinal AbsorptionInjections IntravenousKidney DiseasesBiological half-lifecirculatory and respiratory physiologymedicine.drugEuropean Journal of Drug Metabolism and Pharmacokinetics
researchProduct